| Literature DB >> 24217287 |
Roberta Teta1, Elena Irollo, Gerardo Della Sala, Giuseppe Pirozzi, Alfonso Mangoni, Valeria Costantino.
Abstract
An in-depth study of the secondary metabolites contained in the CaribbeanEntities:
Mesh:
Substances:
Year: 2013 PMID: 24217287 PMCID: PMC3853738 DOI: 10.3390/md11114451
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of smenamide A (1) and B (2).
NMR data of smenamide A (1) (700 MHz, CD3OD).
| Position | δH [Mult., | δC [Mult.] | δH [Mult., | δC [Mult.] | COSY | HMBC | |
|---|---|---|---|---|---|---|---|
| 1 | − | 135.6 (C) | − | 135.6 (C) | |||
| 2/6 | 6.99 (m) | 130.8 (CH) | 6.99 (m) | 130.8 (CH) | 3/5 | 4 | |
| 3/5 | 7.23 (ovl) | 129.4 (CH) | 7.23 (ovl) | 129.4 (CH) | 2/6 | 1 | |
| 4 | 7.23 (ovl) | 128.3 (CH) | 7.23 (ovl) | 128.3 (CH) | 2/6 | ||
| 7 | a | 3.37 (ovl) | 34.8 (CH2) | 3.37 (ovl) | 34.8 (CH2) | 7b, 8 | 1, 2/6, 8, 9 |
| b | 3.19 (m) | 3.19 (m) | 7a, 8 | 2/6 | |||
| 8 | 5.02 (ovl) | 60.5 (CH) | 5.02 (ovl) | 60.5 (CH) | 7a, 7b | ||
| 9 | − | 179.5 (C) | − | 179.5 (C) | |||
| 10 | 5.04 (br. s) | 95.5 (CH) | 5.02 (br. s) | 95.5 (CH) | 8, 11 | ||
| 11 | − | 170.7 (C) | − | 170.7 (C) | |||
| 12 | − | 172.3 (C) | − | 172.2 (C) | |||
| 13 | − | 132.1 (C) | − | 132.1 (C) | |||
| 14 | 1.77 (d, 1.5) | 13.7 (CH3) | 1.78 (d, 1.5) | 13.7 (CH3) | 15 | 12, 13, 15 | |
| 15 | 5.36 (br. d, 10.2) | 144.1 (CH) | 5.36 (br. d, 10.2) | 144.1 (CH) | 14, 16 | ||
| 16 | 2.45 (m) | 33.4 (CH) | 2.48 (m) | 33.4 (CH) | 15, 17, 18a | ||
| 17 | 0.98 (d, 6.5) | 20.4 (CH3) | 1.00 (d, 6.5) | 20.6 (CH3) | 16 | 15, 18, 19 | |
| 18 | a | 1.51 (ovl) | 36.1 (CH2) | 1.52 (ovl) | 35.9 (CH2) | 16, 19a, 19b | 19 |
| b | 1.28 (ovl) | 1.30 (ovl) | 19a, 19b | ||||
| 19 | a | 2.19 (ovl) | 33.2 (CH2) | 2.23 (ovl) | 33.2 (CH2) | 18a, 18b, 19b, 21 | 20, 21 |
| b | 2.06 (ovl) | 2.05 (ovl) | 18a, 18b, 19a, 21 | 20 | |||
| 20 | − | 143.1 (C) | − | 142.8 (C) | |||
| 21 | 5.93 (br. s) | 113.9 (CH) | 5.97 (br. s) | 114.1 (CH) | 19a, 19b | 20, 22 | |
| 22 | a | 2.22 (m) | 28.1 (CH2) | 2.26 (m) | 28.0 (CH2) | 22b, 23 | 20, 21 |
| b | 2.15 (m) | 2.18 (m) | 22a, 23 | 20 | |||
| 23 | 1.64 (m) | 25.9 (CH2) | 1.70 (m) | 26.6 (CH2) | 22a, 22b, 24 | ||
| 24 | 3.36 (ovl) | 48.6 (CH2) | 3.33 (ovl) | 51.5 (CH2) | 23 | 22, 23, 25, 27 | |
| 25 | − | 172.9 (C) | − | 172.7 (C) | |||
| 26 | 2.08 (s) | 21.7 (CH3) | 2.07 (s) | 21.1 (CH3) | 27 | 25 | |
| 27 | 3.03 (s) | 36.6 (CH3) | 2.88 (s) | 33.7 (CH3) | 26 | 24, 25 | |
| OMe | 3.97 (s) | 59.7 (CH3) | 3.97 (s) | 59.7 (CH3) | 9 | ||
Figure 2Most significant correlations provided by the COSY, HMBC, and ROESY 2D NMR spectra of smenamide A (1).
Figure 3Fragment ions observed in the high-resolution ESI MS/MS spectrum of smenamide A (1).
Figure 4Evaluation by MTT assay of Calu-1 cell viability after 72 h of treatment with (A) compound 1 and (B) compound 2. ** P < 0.0005.
Figure 5Evaluation of pro-apoptotic activity of smenamides using the Annexin-V FITC/PI assay. (A) The percentage of apoptosis for cells treated for 72 h with compound 1 at 1, 10, 50, and 100 nM was, respectively, 4%, 4%, 40%, and 80%; the remaining cells remained viable. (B) The percentage of apoptosis for cells treated for 72 h with compound 2 at 1, 10, 50, and 100 nM was, respectively, 6%, 6%, 23%, 40%; the remaining cells remained viable except at concentration of 100 nM, where 47% of cells were necrotic. ** P < 0.0005, * P < 0.001.